HB6867, titled the NIH Clinical Trial Integrity Act, would direct the Department of Health and Human Services, acting through NIH, to impose new requirements on NIH-approved clinical trials in order to increase participation by underrepresented populations. For trials of drugs, devices, biological products, and behavioral interventions, sponsors would have to submit measurable recruitment and retention goals tied to race, ethnicity, age, and sex; explain the basis for those goals; and provide a detailed plan for meeting them. The bill also requires sponsors to address less burdensome follow-up options, such as telehealth, home visits, online follow-up, wearable technology, and alternate labs or imaging sites, and to provide education and training on diversity and health inequities for researchers and reviewers.
The bill further requires ongoing reporting to NIH on participant demographics and retention, with privacy protections, and allows sponsors to justify why certain demographic recruitment is not scientifically necessary or feasible. NIH would have to publish summaries of trial disease prevalence and recruitment goals or justifications, and require remediation plans if trials fail to meet agreed-upon diversity conditions. Existing NIH-funded trials already underway would be exempt, and the bill would also require a GAO study on barriers to participation in federally funded trials and a report to Congress.
Beyond trial-specific requirements, the bill would apply ACA Section 1557 nondiscrimination protections to covered clinical trials and direct HHS to study ways to reduce cost barriers, including reimbursement of out-of-pocket expenses, compensation for participant time, recruitment incentives, and possible safe-harbor changes under anti-kickback rules. It also establishes a national public awareness and education campaign, with grants to community organizations, faith communities, higher education institutions, national advocacy groups, and community pharmacies to improve outreach to underrepresented populations. The bill authorizes $10 million annually for fiscal years 2027 through 2030 for the campaign and related grant activities.
The overall sentiment in the available record appears supportive but procedural, with the bill introduced by bipartisan sponsors and referred to committee without recorded debate or votes. The bill’s purpose is framed around improving equity, access, and scientific validity in clinical research, and its provisions reflect a strong emphasis on inclusion, transparency, and reducing participation burdens. Because there are no committee transcripts or votes provided, there is no documented opposition in the record, though the bill’s reporting, recruitment, and compliance requirements could be viewed as administratively burdensome by trial sponsors and researchers.
If enacted, the bill would add new federal requirements for NIH-approved clinical trials and related HHS/NIH oversight, including demographic recruitment targets, retention reporting, public posting of trial diversity information, remediation plans for underperforming trials, and nondiscrimination coverage under ACA Section 1557. It would also prompt federal studies on cost barriers and barriers to participation, and create a grant-funded outreach program and national education campaign. The bill would affect clinical trial sponsors, NIH reviewers, researchers, community partners, and underrepresented patient populations, while leaving existing ongoing NIH-funded trials exempt from the new requirements.
The available context shows no recorded committee debate or votes, so there is no formal legislative sentiment beyond the bill’s introduction and referral. The bill’s framing and bipartisan sponsorship suggest a generally favorable posture toward improving clinical trial diversity and access. Its language emphasizes equity, health disparities, and practical participation supports, indicating a policy goal that is likely to attract support from patient advocates, minority health organizations, and public health stakeholders.
The main potential points of contention are the bill’s new compliance obligations for clinical trial sponsors and NIH reviewers, including demographic goal-setting, annual reporting, public disclosure, and remediation requirements. Sponsors may also object to the administrative burden of documenting recruitment strategies, training requirements, and follow-up accommodations, especially where trials are small, specialized, or scientifically limited in their ability to recruit certain populations. Another possible area of debate is the bill’s treatment of cost reimbursements and incentives, including whether changes to safe-harbor rules under anti-kickback law are appropriate. The bill anticipates some of these concerns by allowing sponsors to explain when recruitment of particular groups is not scientifically justified or possible and by exempting ongoing NIH-funded trials.